Mesothelioma Risk at Rhode Island Beach Pavilion Being Addressed by Asbestos Abatement

Wednesday, August 18th, 2010

In an effort to reduce risk of mesothelioma and other asbestos-related diseases, asbestos abatement is set to begin August 23 on the Town Beach North Pavilion in Narragansett, Rhode Island.

The Town Beach North Pavilion structure dates back to the 1950s, when asbestos was commonly used in many construction materials. The pavilion presently contains asbestos in the wall paneling and roofing. Plans to replace the pavilion were dropped by the Town Council in June over conflicts regarding the $9.5 million proposal. It was at that time that the Town Council agreed to repair the degrading structure.

Asbestos is a toxic and naturally occurring mineral known to cause terminal health conditions such as malignant mesothelioma, a rare and aggressive cancer. Approximately 2,000 to 3,000 Americans are diagnosed with mesothelioma annually. Prognosis is generally poor since the disease is usually undetected until it has progressed to later stages of development.

The local company Vortex will be performing the asbestos mitigation. Vortex is known for their asbestos removal in Narragansett’s contaminated schools. The company verified the presence of friable asbestos (which can release toxic fibers) in the roofing of the changing rooms and confirmed the asbestos in the wall paneling was encapsulated and safe. The company plans to pressure wash and paint the roofing of the changing rooms, a means of encapsulating and sealing off the asbestos fibers. Thus, the asbestos material itself will not be removed, but covered up to prevent the release of toxic fibers.

Town Manager Grady Miller explains,

Mesothelioma Study Investigates Role of Mesothelin Gene in Cancer Development

Friday, August 13th, 2010

Japanese researchers recently investigated the mechanism by which mesothelin is expressed in malignant mesothelioma. The study was published in the peer-reviewed medical journal Human Pathology.

Mesothelioma is a rare cancer almost exclusively caused by asbestos exposure. Because there is no cure for this disease, the mesothelioma life expectancy for most patients ranges between four and 18 months after diagnosis. Although no cure currently exists, some mesothelioma patients are diagnosed early enough to qualify for a combination of aggressive therapies, such as surgery, chemotherapy and radiation. The combination of therapies, known as multimodality therapy, currently has the best chance of extending a patient’s life expectancy.

Authors of the study explain,

Mesothelioma Diagnosis: Early Detection Broadens Treatment Options

Monday, August 16th, 2010

Although there presently is no cure for mesothelioma, a number of patients are being diagnosed early enough to qualify for aggressive treatments that have the potential to extend life expectancy.

Malignant mesothelioma is a form of cancer almost exclusively caused by asbestos exposure. Asbestos exposure most often occurs when asbestos-containing materials are disturbed, resulting in the release of small, toxic fibers that can be inhaled or ingested.

Fighting the aggressive cancer mesothelioma can be challenging for patients for a number of reasons. For the majority of those who receive a mesothelioma diagnosis, the cancer has already reached an advanced stage of development. This late diagnosis is due to the fact that symptoms of the cancer do not arise until the cancer has reached a later stage of development. In most cases, patients do not begin to experience signs of the cancer until 20 years after their initial exposure to asbestos.

Receiving an accurate mesothelioma diagnosis is difficult, as many physicians can overlook this cancer due to its rarity and the resemblance of its symptoms to other illnesses. Because of these challenges, mesothelioma treatment is often limited to palliative measures rather than curative. However, receiving an early diagnosis can significantly improve a patient’s treatment options and potentially improve life expectancy.

Recent developments in testing for mesothelioma have shown improvement in the early diagnosis of this disease. Mesomark is an easily performed blood test that uses an enzyme-linked test to measure the amount of Soluble Mesothelin-Related Peptides (SMRP) in human serum, which can be present in mesothelioma patients and may be a precursor that could aid in the early diagnosis of the cancer.

Another test, known as miRview Meso, is a microRNA-based molecular diagnostic tool that helps to differentiate pleural mesothelioma from peripheral adenocarcinomas of the lung or metastatic carcinomas involving the lung’s pleural lining. Put simply, this test helps doctors determine if a patient truly has mesothelioma or some other cancer that is similar in appearance.

If a mesothelioma patient is diagnosed during Stage 1 or 2 rather than Stage 3 or 4, attempts at curative surgery may be an option. For those who know they have been exposed to asbestos, the key to receiving an early diagnosis is to seek annual examinations that check for signs of asbestos disease.

Those who may have been exposed to asbestos in the past should explain their exposure history to their doctor. If possible, consulting with a pulmonary physician or oncologist who is experienced in detecting signs of asbestos exposure or dealing with mesothelioma cancer is most beneficial.

Additional information about mesothelioma or asbestos exposure may be found through the Mesothelioma Center.

Review : Proactol The Best Weight Loss Pill I Ever Know

The Weght Loss Pill Review :
Poactol is Old brand weight loss pill, its work best all for you both man and woman (15-65 years old). its safe and guarantee not waste your money.

The worlds 1st clinically proven natural fat-binder. Proven to bind over 27% of dietary fats, this product is so effective it is classified as a medical device (MDD 93/42/EEC). It is backed up by clinical trials and is the only natural diet pill approved by the MHRA (Medicines and Healthcare products Regulatory Agency) - one of the strictest medical regulatory agencies in the world, and it bears their CE stamp of approval!

Less than two years ago when Proactol first came to market we were able to try it and became believers in how well it worked, no other product has surfaced since then to take it off our #1 spot, we though Alli was going to do it but the side effect were too much. So here we are in 2009 still proudly recommnding Proactol for you if you wish to lose weight.

"Proactol is a new and exciting diet pill, and we see it playing a major role in the battle against the bulge. Proven through 4 clinical trials to reduce fat intake from food by up to 28%, if you want results, and you want them quickly and safely, Proactol is our #1 recommendation by far.

How does it work?

Proactol works by binding with the fats in the food you consume, after your meal, you take 1-3 tabs depending on how fatty you feel your meal was. The active ingredient Neoptunia binds with the fat and stops it being absorbed by your intestines, resulting in less fat intake.

Proactol pills come in handy tabs so they are easy to carry around with you, each box contains 120 pills.

Side effects?

Proactol has no know side effects

Just the facts?

Proactol is backed by no less than 8 clinical trials (available on the left)

Below are the main benefits of using Proactol

Proactol is Clinically Proven To:

• Bind up to 28% of dietary fat intake
• Reduce calorie intake from dietary fats
• Help reduce excess body weight
• Suppresses Appetite
• Reduce blood cholesterol levels
• Reduce food cravings
• 6 month Money Back Guarantee

PROACTOL SHOP

Endostatin a new Mesothelioma Medicine

Endostatin

Endostatin is a new Mesothelioma medicine that may help patients. The results of a Phase I trial of Endostatin conducted at the University of Texas revealed promise for patients suffering from this cancer. Most significantly Endostatin was shown to be safer than many alternative therapies. It also showed some effectiveness in combating tumor growth and in two of the twenty five patients caused tumor shrinkage.

The results of the trial seemed to indicate that Endosatin may be safe for non-clinical use. In the trial, the drug exhibited few toxic side effects and was well tolerated by all the participants. The study also reported that the drug slowed the flow of blood in the body in proportion to dosage increases. This effect may be useful in limiting blood flow to tumors so that they become malnurished, stop growing, shrink or even disappear.

During the trial, Endostatin was injected intravenously and as the test went on dosages were increased. To monitor the pharmalogical effects of the drug and the progress of the patient, researchers conducted regular biopsies, PET scans, Computer Tomographies (CT) as well as physical exams. The patients that participated in the trial suffered from a range of cancer types including melanoma, head and neck cancer, renal cell carcinoma, colon cancer, breast cancer, and sarcoma. Though no patients with mesothelioma participated in the trial, researchers feel that Endostatin may hold promise for this type of cancer as well.

The participants of the trial were all patients that were being treated at the University of Texas M.D. Anderson previously. All had undergone standard therapy for their condition but treatment had been unsuccessful. Patient's interested in participating in similar studies should contact their treating physician to learn about the options.

How Endostatin Works: Anti-Angiogenesis

Endostatin is an anti-tumor drug that attacks a process called angiogenesis (sometimes also called an Angiogenic Inhibitor). Angiogenesis is the way that a tumor nourishes itself by forming a network of blood vessels. Essentially the tumor sends out signals that summon blood vessels to nourish them. With this nourishment the tumors grow (or metastasize) and eventually kill the patient. Endostatin is designed to disrupt angiogenesis so that tumors are eventually starved and die.

Until recently, Endostatin had only been tested on laboratory animals. It succeeded in reducing tumors in mice but had not been tested on humans. Currently Endostatin is being tested in clinical trials on terminally ill cancer patients and not long ago Phase I testing concluded at the M.D. Anderson Cancer Center at the University of Texas. The results were generally positive. Endostatin caused few toxic side effects and caused tumor shrinkage in 8% of the participants.

At this writing, there are only three major clinics were Endostatin clinical trials are being conducted with patients: Dana Farber/Partners Cancer Care in Boston, M.D. Anderson Cancer Center in Houston, and the University of Wisconsin Comprehensive Cancer Center in Madison. So far only phase one trials have been conducted and the sample group has been relatively small. Between the three cancer centers, only a 100 or so terminally ill cancer patients have undergone Endostatin treatment. So unfurtunately there are not many oppurtunities to participate in a clinical trial.

Like all Phase I trials, the trials have mostly been concerned with testing the safety of Endostatin. Nevertheless researchers have also paid close attention to Edostatin's anti-angiogenesis effect. All of the patients in the trial are late stage cancer patients so any slowing of the cancers progression as a result of anti-angiogenesis is regarded by researchers as a very encouraging sign. Therefore they have been pleased to see that between roughly 6-8% of the combined group have shown tumor shrinkage.

Since its earliest trials in laboratory mice, doctors and researchers have seen a great deal of potential in Endostatin as a less toxic alternative to conventional cancer treatments such as chemotherapy and radiotherapy. The clinical trials have thus far shown Endostatin to be a safe drug and the medical community remains hopeful that further testing will not only strengthen this verdict, but show Edostatin to be an effective alternative to conventional treatments.

Researchers believe that Endostatin will be most effective treating fast growing cancers with tumors that rely on a larger number of blood vessels such as mesothelioma, renal cell carcinoma, melanoma and breast cancer.